Peter Morgan-Warren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Morgan-Warren has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Clare Bailey
University Hospitals Bristol NHS Foundation Trust, Bristol, UK
2 shared publications - Joachim Höchel
Bayer AG Berlin Germany
2 shared publications - Praveen J. Patel
NIHR Moorfields Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
2 shared publications - Richard Gale
Eye Clinic, York and Scarborough Teaching Hospitals NHS Foundation Trust; Hull York Medical School, University of York, York, UK
2 shared publications Rose Gilbert
Bayer plc, Reading, UK
2 shared publicationsSamia Ezzine
Bayer Inc, Montréal, Canada
2 shared publications
Latest Publications
- Open Access
- 11 July 2026
- Published by Springer Nature in Eye
- Vol. 40 (11) , 1767-1771
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema
- 11 July 2026
- Published by Springer Nature in Eye
- Vol. 40 (11) , 1767-1771
Open AccessSPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema
- Open Access
- 21 May 2026
- Published by Springer Nature in Eye
- Vol. 40 (10) , 1431-1440
Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist
Intravitreal (IVT) anti–vascular endothelial growth factor (anti-VEGF) therapies are the standard of care for retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Despite the favourable efficacy and safety profiles of these therapies, decreasing the treatment burden is still an unmet need because frequent injections may be required over many years. The pharmacokinetic and pharmacodynamic properties of IVT therapies, such as ocular half-life and clearance, can affect the duration of VEGF suppression and thus influence clinical outcomes. Although some properties are inherent to the drug molecule (such as molecular weight, binding affinity and potency) and cannot be altered without changing the structure of the molecule, other factors (such as the dose of the drug) can be increased, which may prolong VEGF suppression time in the eye and, in turn, may lead to a more durable effect of the drug. In addition to pharmacokinetic and pharmacodynamic properties, individual patient factors such as age, surgical history and disease status can also affect the pharmacokinetics, pharmacodynamics and observed effectiveness of a drug. This article reviews the key pharmacological properties of IVT anti-VEGF treatments for nAMD and DMO often referred to in the literature, and aims to elucidate their meaning and clinical relevance for managing retinal diseases.
- 21 May 2026
- Published by Springer Nature in Eye
- Vol. 40 (10) , 1431-1440
Open AccessPharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist
Intravitreal (IVT) anti–vascular endothelial growth factor (anti-VEGF) therapies are the standard of care for retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Despite the favourable efficacy and safety profiles of these therapies, decreasing the treatment burden is still an unmet need because frequent injections may be required over many years. The pharmacokinetic and pharmacodynamic properties of IVT therapies, such as ocular half-life and clearance, can affect the duration of VEGF suppression and thus influence clinical outcomes. Although some properties are inherent to the drug molecule (such as molecular weight, binding affinity and potency) and cannot be altered without changing the structure of the molecule, other factors (such as the dose of the drug) can be increased, which may prolong VEGF suppression time in the eye and, in turn, may lead to a more durable effect of the drug. In addition to pharmacokinetic and pharmacodynamic properties, individual patient factors such as age, surgical history and disease status can also affect the pharmacokinetics, pharmacodynamics and observed effectiveness of a drug. This article reviews the key pharmacological properties of IVT anti-VEGF treatments for nAMD and DMO often referred to in the literature, and aims to elucidate their meaning and clinical relevance for managing retinal diseases.